key: cord-0937700-8rk4ks9p authors: Shi, Hua; Zhou, Chaomin; He, Pinghong; Huang, Sheng; Duan, Youjun; Wang, Xuesheng; Lin, Kexiong; Zhou, Chao; Zhang, Xiangyan; Zha, Yan title: Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection date: 2020-04-13 journal: Int J Antimicrob Agents DOI: 10.1016/j.ijantimicag.2020.105974 sha: e4962123d2cdd3fde905f995332b13382c899e21 doc_id: 937700 cord_uid: 8rk4ks9p Abstract We report a case of a laboratory-confirmed 2019 novel coronavirus infected (known as COVID-19) patient who developed respiratory failure and shock accompanied by persistent diarrhoea despite conventional therapeutic interventions. The patient avoided mechanical ventilation and acquired an immediate clinical and radiological improvement, after treatment of intensive plasma exchange (PE) followed by intravenous immunogloblin (IVIG). Successful therapeutic strategies in our case suggest timely initiating PE treatment followed by IVIG in critically ill patients with COVID-19 may prevent the disease from worsening and help to reduce the requirements for mechanical ventilation and intensive supportive care. What's more, it may improve poor clinical outcomes of these patients. The prevalence of 2019 novel coronavirus infection named by WHO on Feb 11, 2020) has become a growing worldwide concern and caused increasing alarm [1] . By Feb 10, 2020, more than 40,000 people had been infected. There are currently no specific treatments for COVID-19 infection. Supportive treatment combined with existing antiviral agents are the mainstay treatments. More than 1,000 people have lost their lives in the past 2 months. Mortality are as high as 15% in critically ill patients requiring intensive care unit admission and oxygen therapy [1] , suggesting an urgent need to try therapeutic interventions in addition to supportive treatment. We report here a case of a laboratory-confirmed COVID-19 patient who failed to respond to conventional therapeutic interventions and developed respiratory failure and shock accompanied by persistent diarrhoea. The patient avoided mechanical ventilation and acquired an immediate clinical and radiological improvement, after treatment of intensive plasma exchange (PE) followed by intravenous immunogloblin (IVIG). On Jan 21, 2020, a 50-year-old woman with laboratory-confirmed COVID-19 infection was transferred to our hospital for isolated treatment. She had suffered from fever for six days prior to admission with 8-day history of intermittent dry cough, myalgia, fatigue, headache and decreased appetite. In the past, she was healthy apart from a 1-month history of thyroid nodule. 13 days ago, she had a close contact with a permanent resident from Wuhan, where the new coronavirus pneumonia was spreading. She admitted to another hospital about 8 hours ago, laboratory results revealed leukopenia and lymphocytopenia. Computed tomography (CT) revealed bilateral ground-glass opacity. On admission (day of illness 9, DOI 9), vital signs of the patient were within normal limits and no remarkable signs were found on physical examination. Laboratory results were remarkable for leukopenia and lymphocytopenia (white blood cell count (WBC) of 2.6 × 10 9 /L, lymphocyte count of 0.6 × 10 9 /L, absolute neutrophil count 1.7 × 10 9 /L). Blood markers of kidney and liver function were within normal limits. Inflammatory indicators were almost normal (C-reactive protein, CRP was 10.73 mg/L). The patient's clinical course is shown in Fig 1. Upon admission, the patient received low flow oxygen therapy through a nasal catheter and supportive treatment. Antiviral therapy was commenced with inhaled interferon-α2b followed by lopinavir and ritonavir (500mg, orally, twice daily) the next day (DOI 10). Besides, we initiated empirical antibiotic treatment with ceftriaxone. The next day after admission, the patient developed diarrheal characterized by the passage of 6 to 7 loose bowel movements per day, without abdominal pain, nausea or vomiting. No blood and mucus were observed in her feces. Intravenous rehydration, supplement of oral probiotic, antimotility agents and nutritional support treatment were commenced. On Jan 24, 2020(DOI 11), the patient was still suffering from diarrhea and intermittent fever (highest fever, 38.5℃). No remarkable abnormity was found in her stool examination and her admission blood culture was negative. Her condition began to deteriorate at noon, when she reported intermittent cough accompanied by chest pain with the blood pressure dropped to 96/54mmHg. Based on her new symptoms, the patient underwent abdominal and chest CT immediately. Imaging revealed newly developed evidence of lung lesions (Figure 2 ), while abdominal CT scans showed nothing noteworthy. Blood examinations revealed a progressive decrease in white blood cell counts and lymphocyte counts (white blood cell count 2.4×10 9 /L, lymphocyte count 0.5 × 10 9 /L, absolute neutrophil count 1.7 × 10 9 /L). To raise leukocyte count, the patient was medicated with subcutaneous injection of 300ug human granulocyte stimulating factor (GSF) and GSF was discontinued 4 days later. The patient's blood pressure remained low despite adequate volume resuscitation (central venous pressure:6-10cmH 2 0) until low dose vasopressors (dopamine) infused. On Jan 25, 2020(DOI 12), the patient's blood pressure decreased to (Table 1) , which might relate to use of GSF and a possible nosocomial infection. Ceftriaxone was replaced with piperacillin-tazobactam (4.5 g intravenously every 8 hours) based on the deteriorate symptoms and increased serum CRP concentration (35.09mg/L) of the patient. The patient was afebrile, 1 day after initiating methylprednisolone therapy, but her dyspnea aggravated, with persistent diarrhea. Despite the administration of systematic corticosteroid and IVIG, the patient's PO 2 /FiO 2 decreased to 150mmHg on DOI 13, suggesting that she had progressed to acute severe hypoxemic respiratory failure. Laboratory data revealed progressive depletion of lymphocytes (lymphocyte count, 0.3×10 9 /L). In addition, there appeared notable elevation of the serum enzymes and creatine (Table1). CT scans showed bilateral multiple patchy ground-glass opacities and high-density consolidation, which revealed rapidly progressive pulmonary lesions (Fig 2) . Nasal high-flow oxygen therapy was commenced. Furthermore, we initiated the administration of three consecutive sessions of PE with 6000ml plasma (frozen plasma served as the sole replacement solution) followed by 20g IVIG from DOI 14 to DOI 17. The patient's symptoms were almost all relieved, after three consecutive sessions of PE treatment. No adverse events or complications were observed during PE treatment. The oxygenation index increased with oxygen saturation of 96% while the patient was breathing ambient air oxygen and the blood pressure restored and maintained on Jan 29, 2020(DOI 16). Vasopressor therapy and antibiotic treatment were discontinued. Simultaneously, levels of enzymes and creatinine recovered. Although the clinical condition was improved, episodes of diarrheal persisted (frequency: 6-7 times, water lost: 700-1000ml, per day) on DOI16. Stool cultures finalized with no growth and the patient was prescribed with anisodamine (10 mg, daily) intravenously. After a fourth plasma exchange followed by IVIG on DOI 17, the patient made a prompt recovery with no more diarrhea episodes and improved appetite. Her PO2/FiO 2 increased to 302mmHg, coincide with an improving radiographic evidence. On DOI 18, the patient received the sixth treatment of IVIG with the methylprednisolone halved to 20mg and discontinued on DOI 19. Supplemental oxygen was discontinued on DOI 20, with O 2 Sat improved to 95% on room air. Swab samples collected on DOI 16, 18 and 20 from the patient's throat and nasal were negative for 2019 novel coronavirus. The patient was asymptomatic apart from a slight cough, and was discharged from hospital on Feb 5, 2020 (DOI 23) with obvious improvement of chest radiographic evidence, after 15 days of hospitalization. To our knowledge, most patients who are classified into severe type of COVID-19, may need intensive care therapy or even consider, the use of mechanical ventilation for patients with respiratory failure. In the current case, the patient failed to respond to conventional interventions and progressed to persistent diarrhea, acute respiratory failure and shock. Undoubtedly, she belongs to severe type of COVID-19. The timely initiating PE treatment followed by IVIG protected the patient from progressing to acute respiratory distress syndrome (ARDS) and multiple organ failure. Miraculously, the patient made a prompt recovery, without mechanical ventilation and intensive supportive care, after PE treatment. The successful experience in our case suggests that timely treatment with PE followed by IVIG is worth trying, especially in those critically ill patients with COVID-19 infection, since it may significantly improve the prognosis. Our case report sheds new light on therapy strategy for this potentially fatal disease. Unlike previous reported cases, our case patient developed severe diarrhea, which was most likely attribute to the COVID-19 infection. Though diarrhea might be a side effect of lopinavir and ritonavir, no more diarrhea episodes after the fourth PE treatment (followed by IVIG), while lopinavir and ritonavir were continued. This suggests that severe diarrhea is also a clinical manifestation of COVID-19 infection, which may be further confirmed by positive test for COVID-19 in stool specimens [2] . The mechanisms accounting for the immediate improvement of the patient remains to be illustrated. It is most likely that timely treatment with PE followed by IVIG contributed to the prompt recovery of the patient with a favourable prognosis. It has been well documented that the "cytokine storm" may involve in the disease progression of COVID-19 infection in critically ill patients. A previous study reported that COVID-19 patients requiring ICU admission have significantly higher plasma levels of cytokines and chemokines [1] , suggesting the immune system is activated and cytokine storm is formed. In the current case, PE followed by IVIG was initiated when signs of the cytokine storm appeared (that is, decreased oxygenation index, progressively declined lymphocyte count, serum enzymes and creatine levels began to increase, shock, high levels of CRP). The patient presented an immediate clinical and laboratory improvement after initiating PE treatment followed by IVIG. Her lymphocyte count recovered gradually, after intensive treatment of PE. Pathogenic substances, cytokines, as well as inflammatory mediators might be cleared by PE and then the subsequent supplementation of immunoglobulin exerted its immunoregulatory and antiviral effects. This perfect combination treatment produced satisfactory effect. Our speculation is supported by previous studies which demonstrated that PE could decrease serum cytokines, as well as blood viral loads in patients with certain viral infections [3, 4] . Cytokine storm is also believed to be the center of pathophysiology of fatal influenza virus infection. The recovery of three critically ill patients with ARDS and severe shock due to 2009 pH1N1 influenza A virus infection after PE treatment [4] suggests that PE is still effective even in the later stages of cytokine storms. Application of IVIG is associated with decreased loads of viral and improved prognosis during 2009 H1N1 pandemic influenza and SARS, which is also caused by a coronavirus [5, 6] . Unfortunately, we did not evaluate viral loads and cytokine levels before and after plasma exchange. Other mechanisms such as the wide spectrum antibacterial and antiviral specificities of IVIG, as well as the immunomodulatory effects of IVIG [7] should be considered in explaining the resolution of clinical signs in this case. Several questions remained unanswered in our case. First, contributions of antivirus regimens could not be completely ignored, as interferon-α2b and lopinavir and ritonavir were used throughout the course of the treatment. They helped to improve poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections [8] . Second, contributions of corticosteroids could not be excluded since the treatment with PE and IVIG overlapped with the administration of corticosteroid, which possessed anti-inflammatory effects. Timely initiating PE treatment followed by IVIG in critically ill patients with COVID-19 may prevent the disease from worsening and help to reduce the requirements for mechanical ventilation and intensive supportive care. What's more, it may improve poor clinical outcomes of these patients. Randomized controlled trials are urgently needed to confirm the effectiveness of PE combined with the followed IVIG in critically ill COVID-19 patients. Funding: This work was supported in part by grants from the NHC key People's Hospital). Competing Interests: All authors declare no conflict of interest. Ethical Approval: No ethical approval was needed. Written consent was signed by the patient. Clinical features of patients infected with 2019 novel coronavirus in Wuhan First Case of 2019 Novel Coronavirus in the United States Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A--an associated respiratory failure and hemodynamic shock Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections